Omnicell (NASDAQ:OMCL) Releases Q1 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its first quarter 2025 earnings guidance on Friday. The company provided EPS guidance of 0.150-0.250 for the period, compared to the consensus EPS estimate of 0.210. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $260.2 million. Omnicell also updated its FY 2025 guidance to 1.650-1.850 EPS.

Analyst Upgrades and Downgrades

OMCL has been the topic of several recent analyst reports. JPMorgan Chase & Co. dropped their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, March 20th. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Monday. Wells Fargo & Company decreased their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Benchmark reissued a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Finally, Bank of America decreased their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $51.00.

Omnicell Stock Performance

Shares of OMCL opened at $34.74 on Friday. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.75. The company’s 50 day moving average price is $39.16 and its 200 day moving average price is $42.64. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company has a market capitalization of $1.62 billion, a PE ratio of 128.66, a PEG ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Research analysts expect that Omnicell will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.